Northrim BanCorp, Inc. Raises Quarterly Cash Dividend 5.3% to $0.20 per Share

ANCHORAGE, Alaska, Aug. 26, 2016 (GLOBE NEWSWIRE) — Northrim BanCorp, Inc. (NASDAQ:NRIM) today announced that its Board of Directors increased its regular quarterly cash dividend by $0.01, or 5.3%, to $0.20 per share.  The dividend will be payable on September 23, 2016, to shareholders of record at the close of business on September 15, 2016....
Read More →

Hemispherx Biopharma anuncia un logro importante: aprobación de rintatolimod para la venta comercial (nombre comercial en EE. UU.: Ampligen®) para el tratamiento de casos severos de encefalomielitis miálgica/síndrome de fatiga crónica (EM/SFC) en la República Argentina

//
Categories
Primer producto aprobado para la indicación EM/SFC en todo el mundo Esta nueva aprobación abre paso para el crecimiento en Latinoamérica y la Unión Europea PHILADELPHIA, Aug. 26, 2016 (GLOBE NEWSWIRE) —  Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (la “Compañía” o “Hemispherx”), anunció que ha recibido la aprobación de su solicitud de nuevo fármaco (New Drug...
Read More →

Connecticut Water Service, Inc. Declares Dividends

CLINTON, CONNECTICUT, Aug. 26, 2016 (GLOBE NEWSWIRE) — Connecticut Water Service, Inc. (Nasdaq:CTWS) today announced that its Board of Directors declared a quarterly cash dividend of $0.2825 per common share payable on September 15, 2016, for shareholders of record as of September 1, 2016. This quarterly dividend remains unchanged from the previous quarter and represents...
Read More →

Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic

//
Categories
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 26, 2016 (GLOBE NEWSWIRE) — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”), announced that it has received approval of its New Drug Application (NDA) from Administracion Nacional...
Read More →

PositiveID Completes Acquisition of Thermomedics and the Caregiver Non-Contact Thermometer

DELRAY BEACH, Fla., Aug. 26, 2016 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that it has completed its acquisition of Thermomedics Inc., the designer and marketer of the Caregiver® infrared, non-contact thermometer, which is FDA-cleared for clinical use. Under a management services...
Read More →

Byggðastofnun – Árshlutauppgjör janúar – júní 2016

//
Categories
Árshlutareikningur Byggðastofnunar janúar-júní 2016 Árshlutareikningur Byggðastofnunar fyrir tímabilið janúar-júní 2016, var staðfestur af stjórn stofnunarinnar 26. ágúst 2016. Hagnaður tímabilsins nam 45,1 milljón króna.  Eiginfjárhlutfall í lok júní skv. eiginfjárákvæðum laga nr. 161/2002 um fjármálafyrirtæki var 21,73% en var 20,56% í lok árs 2015. Um stofnunina gilda lög um Byggðastofnun nr. 106/1999 og reglugerð nr....
Read More →